RVMDRevolution Medicines, Inc.

Nasdaq revmed.com


$ 44.54 $ 0.84 (1.92 %)    

Monday, 16-Sep-2024 15:59:59 EDT
QQQ $ 473.14 $ -2.10 (-0.44 %)
DIA $ 417.33 $ 2.44 (0.59 %)
SPY $ 562.48 $ 0.83 (0.15 %)
TLT $ 101.29 $ 0.92 (0.92 %)
GLD $ 238.61 $ -0.02 (-0.01 %)
$ 44.54
$ 43.88
$ 44.49 x 100
-- x --
$ 43.88 - $ 44.57
$ 15.44 - $ 48.61
878,874
na
7.44B
$ 0.94
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 02-26-2024 12-31-2023 10-K
4 11-06-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-08-2023 03-31-2023 10-Q
7 02-27-2023 12-31-2022 10-K
8 11-07-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-09-2022 03-31-2022 10-Q
11 02-28-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-11-2021 06-30-2021 10-Q
14 05-10-2021 03-31-2021 10-Q
15 03-02-2021 12-31-2020 10-K
16 11-12-2020 09-30-2020 10-Q
17 08-10-2020 06-30-2020 10-Q
18 05-14-2020 03-31-2020 10-Q
19 03-30-2020 12-31-2019 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-revolution-medicines-maintains-56-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and maintains $56 pric...

 jp-morgan-maintains-overweight-on-revolution-medicines-lowers-price-target-to-54

JP Morgan analyst Eric Joseph maintains Revolution Medicines (NASDAQ:RVMD) with a Overweight and lowers the price target fro...

 wedbush-reiterates-outperform-on-revolution-medicines-maintains-59-price-target

Wedbush analyst Robert Driscoll reiterates Revolution Medicines (NASDAQ:RVMD) with a Outperform and maintains $59 price target.

 needham-maintains-buy-on-revolution-medicines-lowers-price-target-to-61

Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and lowers the price target from $62 to $61.

 revolution-medicines-q2-2024-gaap-eps-081-misses-077-estimate

Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate o...

 barclays-maintains-overweight-on-revolution-medicines-raises-price-target-to-54

Barclays analyst Peter Lawson maintains Revolution Medicines (NASDAQ:RVMD) with a Overweight and raises the price target fro...

 oppenheimer-maintains-outperform-on-revolution-medicines-raises-price-target-to-55

Oppenheimer analyst Jay Olson maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target fro...

 b-of-a-securities-maintains-buy-on-revolution-medicines-raises-price-target-to-55

B of A Securities analyst Alec Stranahan maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target...

 hc-wainwright--co-maintains-buy-on-revolution-medicines-raises-price-target-to-56

HC Wainwright & Co. analyst Robert Burns maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price ta...

 needham-maintains-buy-on-revolution-medicines-raises-price-target-to-62

Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $46 to $62.

 barclays-initiates-coverage-on-revolution-medicines-with-overweight-rating-announces-price-target-of-52

Barclays analyst Peter Lawson initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Overweight rating and announce...

 revolution-medicines-announces-publication-in-cancer-discovery-demonstrating-robust-anti-tumor-activity-of-rason-inhibitors-in-preclinical-models-of-refractory-kras-mutated-non-small-cell-lung-cancer

Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activit...

 revolution-medicines-to-provide-update-on-rmc-6236-pancreatic-ductal-adenocarcinoma-clinical-program-on-july-15-2024-in-investor-webcast

Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS...

 jefferies-initiates-coverage-on-revolution-medicines-with-buy-rating-announces-price-target-of-63

Jefferies initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Buy rating and announces Price Target of $63.

 hc-wainwright--co-reiterates-buy-on-revolution-medicines-maintains-44-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and maintains $44 pric...

 wedbush-maintains-outperform-on-revolution-medicines-raises-price-target-to-46

Wedbush analyst Robert Driscoll maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target f...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION